Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.

Gatta-Cherifi B, Mohammedi K, Cariou T, Poitou C, Touraine P, Raverot G, Brue T, Chanson P, Illouz F, Grunenwald S, Chabre O, Sonnet E and 5 more

Show all authors

Cuny T, Bertherat J, Czernichow S, Frison E, Tabarin A

European journal of endocrinology1 Mar 2024Cited by 19 (Europe PMC)

PMID38450721DOI10.1093/ejendo/lvae024PepBankPUB-38450721

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with craniopharyngioma-related obesity, weight loss did not significantly differ between exenatide and placebo.
In plain wordsIn adults with craniopharyngioma-related obesity, weight loss did not significantly differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous twice daily · 26 weeksAs given in this study (human).
Measurements
Weight change
−3.8 kg
Exenatide
Weight change
−1.6 kg
Placebo
Adjusted treatment difference
−3.1 kg
Exenatide versus placebo
Source sentences
Summary
The adjusted mean treatment difference was -3.1 kg (95% confidence interval [CI] -7.0 to 0.7, P = 0.11).
4 context sentences(design, population, supporting numbers)
Summary · context
At week 26, weight decreased from baseline by a mean of -3.8 (SD 4.3) kg for exenatide and -1.6 (3.8) kg for placebo.
Summary · context
The primary outcome was the mean change in body weight at week 26 in the intention-to-treat population.
Summary · context
A double-blind multicenter superiority randomized clinical in trial in two parallel arms.
Summary · context
Adults with CRO (body mass index > 30 kg/m²) without the sign of recurrence of craniopharyngioma in the past year.InterventionsExenatide or placebo injected subcutaneously twice a day during 26 weeks.
Report a problemFND-3845072101
02HumanRandomized controlled trialEfficacy outcome
In adults with craniopharyngioma-related obesity, results supported a greater hunger score reduction with exenatide than placebo.
In plain wordsIn adults with craniopharyngioma-related obesity, results supported a greater hunger score reduction with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHunger score
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · subcutaneous twice daily · 26 weeksAs given in this study (human).
Measurements
Treatment difference in hunger score change
−2.3 score
Exenatide versus placebo
Source sentences
Summary
Results were compatible with a higher reduction of hunger score with exenatide compared with placebo (estimated treatment difference in change from baseline to week 26: -2.3, 95% CI -4.5 to -0.2), while all other outcomes did not significantly differ between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind multicenter superiority randomized clinical in trial in two parallel arms.
Summary · context
Adults with CRO (body mass index > 30 kg/m²) without the sign of recurrence of craniopharyngioma in the past year.InterventionsExenatide or placebo injected subcutaneously twice a day during 26 weeks.
Report a problemFND-3845072102
03HumanRandomized controlled trialEfficacy outcome
In adults with craniopharyngioma-related obesity, other secondary outcomes did not significantly differ between exenatide and placebo.
In plain wordsIn adults with craniopharyngioma-related obesity, other secondary outcomes did not significantly differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeOther secondary outcomes
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Overall treatment effect · Whole body
Studied dose
Dose not stated · subcutaneous twice daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Results were compatible with a higher reduction of hunger score with exenatide compared with placebo (estimated treatment difference in change from baseline to week 26: -2.3, 95% CI -4.5 to -0.2), while all other outcomes did not significantly differ between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were eating behavior, calories intake, energy expenditure, cardiovascular, metabolic risk factor, quality of life, and the tolerance profile.
Summary · context
A double-blind multicenter superiority randomized clinical in trial in two parallel arms.
Summary · context
Adults with CRO (body mass index > 30 kg/m²) without the sign of recurrence of craniopharyngioma in the past year.InterventionsExenatide or placebo injected subcutaneously twice a day during 26 weeks.
Report a problemFND-3845072103
04HumanRandomized controlled trialSafety outcome
In adults with craniopharyngioma-related obesity, adverse events were more common with exenatide than placebo.
In plain wordsIn adults with craniopharyngioma-related obesity, adverse events were more common with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneous twice daily · 26 weeksAs given in this study (human).
Measurements
Participants with adverse events
95%
Exenatide
Participants with adverse events
19 participants
Exenatide
Participants with adverse events
70%
Placebo
Participants with adverse events
14 participants
Placebo
Adverse events
108 events
Exenatide
Adverse events
54 events
Placebo
Source sentences
Summary
Adverse events were more common with exenatide versus placebo, and occurred in, respectively, 19 (95%) participants (108 events) and 14 (70%) participants (54 events).
2 context sentences(design, population, supporting numbers)
Summary · context
A double-blind multicenter superiority randomized clinical in trial in two parallel arms.
Summary · context
Adults with CRO (body mass index > 30 kg/m²) without the sign of recurrence of craniopharyngioma in the past year.InterventionsExenatide or placebo injected subcutaneously twice a day during 26 weeks.
Report a problemFND-3845072104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT02860923

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

University Hospital, Bordeauxn = 4211 Jan 2017 to 30 Sept 2018

Craniopharyngiomas · Hypothalamic Obesity

Trial page ClinicalTrials.govUpdated 22 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.